Table 3.
EC50/focus reduction assay and alterations in ORF40 of 35B2-resistant clones
| Clone | EC50/FRA (μM)a | Amino acid change(s) in: |
||||
|---|---|---|---|---|---|---|
| ORF40 | ORF62 | ORF0 | ORF1 | ORF31 | ||
| V-Oka | 1.8 ± 0.2 | |||||
| V-Oka-YSR | 1.1 ± 0.5 | |||||
| R1 | 37.6 ± 4.1 | L196F | H275R | S197G | L52P | S88A |
| R2 | 4.2 ± 0.2 | F1110S | V733A, Q1215R | — | — | — |
| R3 | 3.5 ± 0.5 | V80A, A1078T | —b | — | — | — |
| R4 | 28.8 ± 1.6 | F1093S | Several | I106V | — | — |
| G01 | 14.0 ± 2.8 | T12I | — | NDc | ND | ND |
| G02 | 26.3 ± 3.8 | T192A | — | ND | ND | ND |
| G03 | 32.8 ± 4.5 | C93R | — | ND | ND | ND |
| G04 | 9.4 ± 1.3 | F1110S | — | ND | ND | ND |
| G08 | 6.0 ± 0.7 | V184F | — | ND | ND | ND |
| G09 | 17.3 ± 1.3 | F79L | — | ND | ND | ND |
| G11 | 16.4 ± 1.5 | V1094F | — | ND | ND | ND |
| G15 | 18.5 ± 1.6 | V1094F | — | ND | ND | ND |
| G17 | 25.2 ± 0.7 | V343I | — | ND | ND | ND |
| G18 | 25.0 ± 0.3 | F96C | — | ND | ND | ND |
| G10 | 10.8 ± 0.2 | F1110S | ND | ND | ND | ND |
| G13 | ND | F1110S | ND | ND | ND | ND |
| G16 | ND | C93R | ND | ND | ND | ND |
| G28 | >40 | L196F | ND | ND | ND | ND |
| G29 | 31.5 ± 0.6 | T192A | ND | ND | ND | ND |
| G31 | >40 | F79I | ND | ND | ND | ND |
| G32 | 6.1 ± 0.3 | Q962L | ND | ND | ND | ND |
| G36 | ND | C93R | ND | ND | ND | ND |
| G40 | 22.2 ± 1.2 | V343I | ND | ND | ND | ND |
| G41 | ND | F1110S | ND | ND | ND | ND |
a
EC50s were obtained by the focus reduction assay (FRA).
b
—, no alteration.
c
ND, not determined.